Risk of progression to AML in patients with MDS treated with lenalidomide

Trial Profile

Risk of progression to AML in patients with MDS treated with lenalidomide

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2010

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Dec 2010 Results presented at the 52nd Annual Meeting of the American Society of Hematology, according to a Celgene media release.
    • 08 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top